ImCheck Therapeutics awarded €2 million from Bpifrance to advance its first-in-class immunotherapy program into the clinic
| Financial & Business
Bpifrance views ImCheck’s projects as unique and well-positioned
ImCheck Therapeutics, a biotech company on the cutting…
ImCheck Therapeutics appoints Paul Frohna MD, PhD, PharmD, as Chief Medical Officer
| Leadership & Corporate
Paul Frohna brings over 15 years of experience in translational medicine and clinical and regulatory strategy
ImCheck…
The French Région Sud and the European Union provide grant funding to Imcheck Therapeutics and its development of a new generation of cancer treatments
| Financial & Business
Through a 717 K€ grant co-financed by the Région Sud and the European Union under the ERDF, ImCheck has received…
Award for ImCheck Therapeutics at the Aix-Marseille Innovation Awards
| Leadership & Corporate
ImCheck Therapeutics awarded Innovation Start-up of the Year in Healthcare at the Aix-Marseille Innovation awards.
The…
ImCheck Therapeutics Appoints Prof. René Hoet, PhD, as Chief Scientific Officer
| Science & Medicine
ImCheck Therapeutics, an emerging biopharmaceutical company developing novel immune modulators against cancer and…
ImCheck Therapeutics appoints Dr. Debasish Roychowdhury as its independent Chairman of the Board
| Leadership & Corporate
With over a decade of patient care as a hematologist/oncologist and a career as a big pharma senior executive in R&D,…
ImCheck Therapeutics obtains 1M€ from Bpifrance to contribute to the development of a novel therapeutic antibody in immuno-oncology
| Financial & Business
First non-dilutive funding received by ImCheck following its initial fundraising of 20 M€ in May 2017
ImCheck Therapeutics raises €20 Million and appoints its CEO
| Financial & Business
Emerging leader in immuno-oncology accelerates its development programs and prepares for entry into the clinic